As of 2025-07-16, the EV/EBITDA ratio of Coherus BioSciences Inc (CHRS) is -3.10. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. CHRS's latest enterprise value is 316.85 mil USD. CHRS's TTM EBITDA according to its financial statements is -102.37 mil USD. Dividing these 2 quantities gives us the above CHRS EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 10.1x - 14.2x | 12.2x |
| Forward P/E multiples | 14.9x - 27.9x | 20.9x |
| Fair Price | (10.79) - (0.30) | (6.62) |
| Upside | -1298.6% - -133.1% | -835.8% |
| Date | EV/EBITDA |
| 2025-07-15 | -3.04 |
| 2025-07-14 | -3.15 |
| 2025-07-11 | -3.07 |
| 2025-07-10 | -3.06 |
| 2025-07-09 | -3.06 |
| 2025-07-08 | -3.00 |
| 2025-07-07 | -2.92 |
| 2025-07-03 | -2.99 |
| 2025-07-02 | -2.98 |
| 2025-07-01 | -2.94 |
| 2025-06-30 | -2.90 |
| 2025-06-27 | -2.92 |
| 2025-06-26 | -2.91 |
| 2025-06-25 | -2.89 |
| 2025-06-24 | -2.95 |
| 2025-06-23 | -2.90 |
| 2025-06-20 | -2.92 |
| 2025-06-18 | -2.95 |
| 2025-06-17 | -2.93 |
| 2025-06-16 | -2.97 |
| 2025-06-13 | -2.94 |
| 2025-06-12 | -2.97 |
| 2025-06-11 | -2.99 |
| 2025-06-10 | -2.99 |
| 2025-06-09 | -3.04 |
| 2025-06-06 | -3.02 |
| 2025-06-05 | -2.99 |
| 2025-06-04 | -2.98 |
| 2025-06-03 | -2.96 |
| 2025-06-02 | -2.94 |
| 2025-05-30 | -2.96 |
| 2025-05-29 | -2.98 |
| 2025-05-28 | -2.98 |
| 2025-05-27 | -2.96 |
| 2025-05-23 | -2.93 |
| 2025-05-22 | -2.95 |
| 2025-05-21 | -2.95 |
| 2025-05-20 | -3.00 |
| 2025-05-19 | -2.98 |
| 2025-05-16 | -2.94 |
| 2025-05-15 | -2.95 |
| 2025-05-14 | -2.97 |
| 2025-05-13 | -3.01 |
| 2025-05-12 | -3.23 |
| 2025-05-09 | -3.17 |
| 2025-05-08 | -3.20 |
| 2025-05-07 | -3.15 |
| 2025-05-06 | -3.13 |
| 2025-05-05 | -3.23 |
| 2025-05-02 | -3.32 |